To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2009 News Releases

About RSS

Update on Astellas' Complaint Challenging the FDA's decision for Citizen Petition in the US

November 26, 2009

Tokyo, Japan, November 26, 2009 – Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that its North American affiliate, Astellas Pharma US, Inc. (“Astellas Pharma US”; headquarters: Deerfield, IL) has dismissed its lawsuit against the U.S. Food and Drug Administration (FDA). 

As stated in the press release issued on August 13, 2009, Astellas Pharma US filed the lawsuit on August 11, 2009 after FDA substantially denied the company’s Citizen Petition regarding the safe and effective use of oral immunosuppressants used in organ transplant patients. 
 *About Citizen Petition
A Citizen Petition is a formal request asking FDA to issue, change or cancel a regulation, or to take other actions under the laws administered by the agency. FDA receives about 200 petitions yearly.

Printer-friendly version

Main Text end
Local Navigation
Local Navigation end
Related Links